1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-196, 2008-007167-16, NCT00883116
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and older
Sponsor: NCI
Protocol IDs: GOG-0258, GOG-0258, NCT00942357
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MMC-01-09-227, NCT00231868
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 06US03IMP-852A [Cooley], MT2006-02, NCT00319748
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-062, 7713, PHL-062, NCT00478426
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007CO008, NCT00513786
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2007-0324, NCT00626561
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-685, version Feb. 14, 2008, NCT00483327
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EndoRT, WIRB PRO NUM: 20050247, NCT00285415
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-205, NCT00739830
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.26, NCT00748709
|
|
14.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20806, NCT00879359
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM104-B-001-09, NCT00900562
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC0845, MC0845, 8233, NCT01010126
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0086P, GOG-0086P, NCT00977574
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0921, RTOG-0921, NCT01005329
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL147-201, NCT01013324
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MMC-08-03-060, NCT01041027
|
|
22.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UVACC-SCC-0102, WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 0407007343, NCT00283075
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 803776, UPCC 03505, NCT00299962
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06C.549, NCT00437372
|
